The Venture Codex

Participated · Seed · Jan 2026

Xella Health is a San Francisco–based women’s precision health company creating multi-omic diagnostics that decode female biology by simultaneously analyzing menstrual fluid and peripheral blood. The platform targets conditions that uniquely, differently, or disproportionately affect women, including fertility challenges, hormonal imbalances, perimenopause, and early-stage cancers. Each customer is paired with a dedicated clinician-coach who is supported by AI, ensuring complex molecular data is translated into actionable care plans rather than just additional information. The company positions itself as foundational infrastructure for women’s health, combining deep biology with clinical translation and accountability to outcomes. Xella Health has raised $3.7 million in pre-seed capital to accelerate product development and clinical validation. No operating metrics such as revenue or user counts were disclosed in the article.

Participated · Equity · Nov 2025

MiSalud Health offers a bilingual healthcare platform that combines an open-sourced large language model with culturally competent physicians and health coaches to automate administrative tasks, improve health literacy, and deliver personalized care. The service reaches employees in agriculture, construction, manufacturing, and hospitality through job-site events and virtual consultations, making quality care more accessible and affordable for underserved communities. MiSalud’s AI assists clinicians by streamlining workflows, thereby lowering costs and enhancing patient engagement. The company currently serves over 100,000 members across North America. With its latest capital infusion, MiSalud plans to expand operations into 20 additional U.S. states and roll out services that traditionally require in-person visits. Including the newest financing, MiSalud has raised a total of $18.3 million from venture investors.

Participated · Series A · Oct 2025

Founded in 2020 by Harvard Business School classmates Tina Keshani, Julia Cole, and Sophia Richter, Seven Starling delivers technology-enabled maternal mental-health care. Its platform combines clinical evaluations, medication management, and both individual and group therapy to treat depression, anxiety, and related conditions tied to parenthood. All services are covered by insurance, helping patients access support without prohibitive out-of-pocket costs. The company plans to use new capital to expand into a dozen additional states by the end of 2026. Seven Starling’s care model targets postpartum, infertility, miscarriage, and loss, aiming to close gaps in traditional maternal health services. To date, the startup has raised $21.8 million across three rounds, giving it resources to scale its virtual operations and provider network.

Led · Seed · Sep 2025

TrueMeter offers an AI energy-savings platform that combines automated rate optimization, consolidated billing, predictive analytics and real-time operational intelligence for restaurants, retailers and hospitality chains. The platform automates instant switching to lower electricity rates, collective gas procurement, rate-plan optimization and automated utility bill auditing, and it can detect energy theft and equipment inefficiencies via anomaly detection. TrueMeter delivers 7–15% savings with zero upfront investment and has reported $3M+ in customer savings while processing millions in gross energy spending. Since launching in March 2024 the company has grown to serve over 500 business locations, including customers such as Yoshinoya, Fresh Direct, Misfits Markets and Local Kitchens. The company plans to use the new funding to expand its engineering team, accelerate customer acquisition, and further enhance its AI-powered optimization platform. TrueMeter was founded in 2023 by Stanford graduates Ali Sarilgan and Dr. Ozge Islegen-Wojdyla and is based in San Francisco.

Participated · Equity · Jun 2025

Empo Health has developed an at-home diabetic foot ulcer (DFU) monitoring system that pairs the FDA-listed Empo Footprint imaging scale with the HIPAA-compliant Empo Remote Health Link service. Patients step on the Footprint scale to generate a full-color visual image of their feet that is automatically transmitted to care teams for early detection and follow-up. In a pilot study Empo demonstrated near-daily patient engagement and detected early indications of ulcers in half of participants. The company emphasizes ease-of-use to increase adoption among high-risk neuropathy patients and to give clinicians actionable remote data. Empo was incorporated in 2020, is based in the San Francisco Bay Area (San Bruno, Calif.), and was founded by MIT- and Stanford-trained technical founders. The company is supported by venture and angel investors and SBIR grants, and is commercializing its solution while initiating further studies with partners such as Carilion Clinic. Financially, Empo recently closed a $7M financing, bringing total capital raised to date to $15M. Empo Health develops a patented in-home monitoring system built around a smart bathroom scale that detects changes in daily foot scans to enable early detection of diabetic foot ulcers (DFUs). The company aims to eliminate severe DFUs by integrating monitoring into patients’ daily routines and delivering actionable data to medical professionals. DFUs affect up to 26 million people each year, and Empo positions its product to reduce serious complications through earlier intervention. Empo’s technology is designed to fit seamlessly into daily use, providing crucial information to clinicians for informed care decisions. SeaX Ventures has invested in the seed-stage startup, signaling early external backing. SeaX’s founder described Empo’s technology as a game-changer and cited prior market issues with false positives and cumbersome user experiences that Empo seeks to address.